Sei Investments Co. Purchases New Position in Corvus Pharmaceuticals, Inc. $CRVS

Sei Investments Co. purchased a new position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 60,848 shares of the company’s stock, valued at approximately $890,000. Sei Investments Co. owned 0.07% of Corvus Pharmaceuticals at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. SEB Asset Management AB acquired a new stake in Corvus Pharmaceuticals in the first quarter valued at approximately $3,319,000. Bank of New York Mellon Corp raised its stake in shares of Corvus Pharmaceuticals by 40.8% during the 1st quarter. Bank of New York Mellon Corp now owns 185,347 shares of the company’s stock worth $2,712,000 after buying an additional 53,719 shares during the period. Emerald Mutual Fund Advisers Trust purchased a new position in shares of Corvus Pharmaceuticals during the 1st quarter valued at approximately $6,719,000. Emerald Advisers LLC purchased a new position in shares of Corvus Pharmaceuticals during the 1st quarter valued at approximately $10,039,000. Finally, Teachers Retirement System of The State of Kentucky acquired a new stake in Corvus Pharmaceuticals in the 1st quarter valued at $117,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Weiss Ratings raised shares of Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. LADENBURG THALM/SH SH upgraded shares of Corvus Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, July 30th. The Goldman Sachs Group initiated coverage on shares of Corvus Pharmaceuticals in a research note on Friday, April 17th. They set a “buy” rating and a $40.00 target price for the company. Finally, Wall Street Zen downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $33.33.

Key Headlines Impacting Corvus Pharmaceuticals

Here are the key news stories impacting Corvus Pharmaceuticals this week:

• Positive Sentiment: An independent analysis examines soquelitinib’s clinical science, commercial market opportunity and fair value, keeping attention focused on the potential upside from Corvus’s lead program. The stock has increased from its 52-week low, suggesting investors continue to assign meaningful value to the drug’s development prospects. Corvus: Evaluating Soquelitinib’s Science, Market Reach, And Fair Value
• Neutral Sentiment: HC Wainwright issued a new FY2030 earnings forecast for Corvus. The article does not provide the estimate, but the long-range projection indicates analysts are continuing to model the company’s path toward commercialization and profitability. FY2030 Earnings Forecast for CRVS Issued By HC Wainwright
• Negative Sentiment: HC Wainwright lowered EPS estimates across multiple periods: FY2026 to a loss of $0.83 from $0.66, FY2027 to a loss of $0.80 from $0.63, FY2028 to a loss of $0.37 from $0.25, and FY2029 to a loss of $0.01 from a profit of $0.07. Quarterly estimates were also reduced, including Q3 2026 to a loss of $0.23 from $0.17 and Q1–Q4 2027 to losses ranging from $0.16 to $0.24 per share. These revisions imply slower progress toward profitability and could pressure sentiment. HC Wainwright Earnings Estimate Revisions for Corvus Pharmaceuticals

Insiders Place Their Bets

In other Corvus Pharmaceuticals news, Director David Scott Moore purchased 21,700 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were purchased at an average cost of $11.53 per share, for a total transaction of $250,201.00. Following the completion of the transaction, the director owned 21,700 shares of the company’s stock, valued at $250,201. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 19.70% of the company’s stock.

Corvus Pharmaceuticals Stock Performance

NASDAQ CRVS opened at $15.14 on Friday. The business has a fifty day moving average price of $13.64 and a 200 day moving average price of $15.14. The company has a market cap of $1.27 billion, a P/E ratio of -24.82 and a beta of 0.87. Corvus Pharmaceuticals, Inc. has a one year low of $4.70 and a one year high of $26.95.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its earnings results on Thursday, August 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.03). As a group, sell-side analysts predict that Corvus Pharmaceuticals, Inc. will post -0.79 EPS for the current fiscal year.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.